Generate Biomedicines (NASDAQ:GENB) Stock Price Up 7.6% – What’s Next?

Shares of Generate Biomedicines Inc (NASDAQ:GENB) traded up 7.6% during mid-day trading on Tuesday . The stock traded as high as $15.38 and last traded at $15.4630. 33,735 shares were traded during mid-day trading, a decline of 93% from the average session volume of 454,893 shares. The stock had previously closed at $14.37.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Guggenheim assumed coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price target for the company. HC Wainwright increased their target price on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Zacks Research raised shares of Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Wall Street Zen downgraded shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Price Performance

The firm’s 50 day moving average is $12.88.

Generate Biomedicines (NASDAQ:GENB) last released its earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.